KU-55933

TargetMol
Product Code: TAR-T2685
Supplier: TargetMol
CodeSizePrice
TAR-T2685-5mg5mg£105.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2685-1mL1 mL * 10 mM (in DMSO)£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2685-10mg10mg£119.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2685-25mg25mg£153.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2685-50mg50mg£204.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2685-100mg100mg£302.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor.
CAS:
587871-26-9
Formula:
C21H17NO3S2
Molecular Weight:
395.49
Pathway:
PI3K/Akt/mTOR signaling; DNA Damage/DNA Repair; Autophagy
Purity:
0.998
SMILES:
O=c1cc(oc(c1)-c1cccc2Sc3ccccc3Sc12)N1CCOCC1
Target:
ATM/ATR; DNA-PK; PI3K; mTOR; Autophagy

References

1. Hickson I, et al. Cancer Res. 2004, 64(24), 9152-9159. 2. Soleimani R, et al. Aging. 2011, 3(8), 782-793. 3. Ivanov VN, et al. Cancer Res. 2009, 69(8), 3510-3519. 4. Hu L, Li B, Chen G, et al. A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe. Journal of Experimental & Clinical Cancer Research. 2020, 39(1): 1-14. 5. Huang C Y, Hsieh F S, Wang C Y, et al. Supplementary Methods Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ATM-mediated DNA damage response. EUROPEAN JOURNAL OF CANCER.